Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS).

ABSTRACT:

Background

In animal studies, hydrogen sulfide (H₂S) has been shown to protect the heart from ischemia-reperfusion injury. This study evaluates the safety and tolerability of the H₂S donor sodium thiosulfate (STS) in patients with acute coronary syndrome (ACS).

Methods

Eighteen patients, undergoing coronary angiography for ACS, received STS intravenously immediately after arrival at the catheterization laboratory according to a "3 + 3 dose-escalation design" with fixed dosing endpoint (0, 2.5, 5, 10, 12.5, and 15 grams). This first dose STS was combined with verapamil and nitroglycerin required for transradial procedures. A second dose STS was administered 6 hours later. Primary endpoint was dose-limiting toxicity, defined as significant hemodynamic ins

SUBMITTER: de Koning MLY 

PROVIDER: S-EPMC7532357 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature